Le Groupe Menarini et NewAmsterdam Pharma obtiennent l'autorisation de la Commission européenne pour Ubeslo® (obicetrapib en monothérapie) et Evlarco® (association à dose fixe d'obicetrapib et d'ézétimibe)
- Homologation d'une thérapie novatrice appuyée par les essais de phase 3 BROADWAY, BROOKLYN et TANDEM, ayant démontré des réductions significatives du LDL-C associées à un profil de tolérance favorable - - La première approbation réglementaire mondiale accordée à l'obicetrapib marque une...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Federal Aviation Administration Extends Solace Partnership to Support National Airspace System Modernization
- Hollyland presenta LARK M3: un sistema de audio inalámbrico flexible
- Charter Next Generation Names Todd Herndon Chief Financial Officer
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,200+ — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →